The National Medical Products Administration (NMPA) has released plans to facilitate the approval processes for highly clinical demanded and rare disease medicines, and R&D of new drugs in the new year, as reported by Yicai on January 21. Meanwhile, the authority will also put emphasis on the reform of government services in the medical and pharmaceutical industry, the enhancement of the legal system, and supervision over security and high-risk products. For marketed drugs, NMPA intends to revise laws related to the production, distribution, inspection, and detection of drugs, refine the management procedures, strengthen the regulations of vaccine manufacturing, and improve the information traceability system.